
An experimental ‘supercharged’ form of popular GLP-1 weight-loss meds could help ease fatty liver disease, a new trial suggests. The drug under development, survodutide, helped up to 83% of patients gain real improvements in markers of fatty liver disease, a widespread and potentially lethal condition often linked to obesity. Right now, there’s only one drug,… read on > read on >